Good news for sun worshipers:
An experimental vaccine combination could provide a big step forward in cancer treatment. A study found a combination of Moderna's personalized melanoma vaccine and Merck & Co's immunotherapy Keytruda brought down the risk of recurrence or death by 44-percent. In an interview with Reuters, Moderna's chief medical officer said the combination "has the capacity to be a new paradigm in the treatment of cancer." Moderna's personalized vaccine is created using patients' tumors and healthy tissue and can be made in around eight weeks